Last reviewed 2026-04-23 · How we verify

IVF: Decapeptyl and hCG

IVF: Decapeptyl and hCG is a GnRH agonist + gonadotropin Small molecule drug developed by The University of Hong Kong. It is currently in Phase 3 development for Infertility requiring in vitro fertilization (IVF) with controlled ovarian hyperstimulation. Also known as: IVF: hCG.

Decapeptyl (triptorelin) suppresses gonadotropin-releasing hormone (GnRH) to downregulate the pituitary-gonadal axis, while hCG (human chorionic gonadotropin) triggers final oocyte maturation and ovulation in assisted reproductive technology.

Decapeptyl (triptorelin) suppresses gonadotropin-releasing hormone (GnRH) to downregulate the pituitary-gonadal axis, while hCG (human chorionic gonadotropin) triggers final oocyte maturation and ovulation in assisted reproductive technology. Used for Infertility requiring in vitro fertilization (IVF) with controlled ovarian hyperstimulation.

At a glance

Mechanism of action

This combination is used in controlled ovarian hyperstimulation for in vitro fertilization. Decapeptyl acts as a GnRH agonist to prevent premature luteinizing hormone (LH) surge by initially stimulating then desensitizing GnRH receptors. hCG mimics the natural LH surge to induce final meiotic maturation of oocytes and trigger ovulation, allowing synchronized egg retrieval for fertilization.

Approved indications

• Infertility requiring in vitro fertilization (IVF) with controlled ovarian hyperstimulation

Common side effects

• Ovarian hyperstimulation syndrome (OHSS)
• Headache
• Hot flushes
• Injection site reactions
• Mood changes
• Abdominal discomfort

Key clinical trials

• Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
• GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET (PHASE3)
• Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility (NA)
• Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (PHASE1, PHASE2)
• IVF Treatment in Women With Immature Oocytes in Previous Cycle (NA)
• A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703) (PHASE3)
• Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin (NA)
• DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IVF: Decapeptyl and hCG CI brief — competitive landscape report
• IVF: Decapeptyl and hCG updates RSS · CI watch RSS
• The University of Hong Kong portfolio CI

Frequently asked questions about IVF: Decapeptyl and hCG

Related

• Drug class: All GnRH agonist + gonadotropin drugs
• Target: All drugs targeting GnRH receptor (Decapeptyl); LH/hCG receptor (hCG)
• Manufacturer: The University of Hong Kong — full pipeline
• Therapeutic area: All drugs in Reproductive Medicine / Fertility
• Indication: Drugs for Infertility requiring in vitro fertilization (IVF) with controlled ovarian hyperstimulation
• Also known as: IVF: hCG
• Compare: IVF: Decapeptyl and hCG vs similar drugs
• Pricing: IVF: Decapeptyl and hCG cost, discount & access